Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company covers the event date of January 1, 2021, with the report filed on January 4, 2021. The filing addresses the status of the Biologics License Application (BLA) for lisocabtagene maraleucel ("liso-cel") and the consequent termination of the Bristol-Myers Squibb Contingent Value Rights (CVRs).
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the status of a specific contingent liability and equity instrument.
Material Changes
- Regulatory Status: The U.S. Food and Drug Administration (FDA) has not issued a decision on the BLA for liso-cel for the treatment of adults with relapsed or refractory large B-cell lymphoma as of December 31, 2020.
- CVR Termination: Because the FDA approval milestone was not met by the December 31, 2020 deadline, the Contingent Value Rights Agreement terminated automatically on January 1, 2021.
- Trading Status: The Bristol-Myers Squibb Contingent Value Rights (BMY RT) are no longer eligible for payment and will cease trading on the New York Stock Exchange.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement that the liso-cel application remains under FDA review. The primary risk disclosed is the failure to meet the specific regulatory milestone required to trigger payment under the CVR Agreement, resulting in the extinguishment of the CVRs. No forward-looking guidance regarding future financial performance or other product approvals is provided in this specific filing.
Investor Verification Checklist
- Verify the current trading status of BMY RT on the NYSE to confirm delisting.
- Review the attached press release (Exhibit 99.1) for details on the FDA review timeline for liso-cel.
- Confirm the terms of the CVR Agreement to understand the specific milestones that were missed.
- Monitor future filings for updates on the FDA decision for liso-cel, as the application remains under review.